Protection against murine intestinal amoebiasis induced by oral immunization with the 29kDa antigen of Entamoeba histolytica and cholera toxin

Experimental Parasitology

Volumn 126, Issue 3, 2010, Pages 359-365

  Carrero, J C ^a   Contreras Rojas, A ^a   Sanchez Hernandez B ^a   Petrosyan, P ^a   Bobes, R J ^a   Ortiz Ortiz, L ^a   Laclette, J P ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Eh29; Intestinal amoebiasis; Protection; Secretory IgA; Trophozoites adherence

Indexed keywords

CHOLERA TOXIN B SUBUNIT; ENTAMOEBA HISTOLYTICA 29 ANTIGEN; ENTAMOEBA HISTOLYTICA 29 ANTIGEN CHOLERA TOXIN B SUBUNIT; GANGLIOSIDE GM1; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PARASITE ANTIGEN; PROTOZOAL VACCINE; UNCLASSIFIED DRUG; 29 KDA ANTIGEN, ENTAMOEBA HISTOLYTICA; CHOLERA TOXIN; HYBRID PROTEIN; IMMUNOGLOBULIN G; MEMBRANE ANTIGEN; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN; SECRETORY IMMUNOGLOBULIN;

AMEBIASIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DRUG EFFICACY; ENTAMOEBA HISTOLYTICA; ENZYME LINKED IMMUNOSORBENT ASSAY; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TROPHOZOITE; ANIMAL; BIOSYNTHESIS; BLOOD; C3H MOUSE; CECUM; DISEASE MODEL; DYSENTERY, AMEBIC; GERMFREE ANIMAL; HAMSTER; HUMAN; IMMUNIZATION; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; PARASITOLOGY; PATHOLOGY; PROCEDURES;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; CECUM; CHOLERA TOXIN; CRICETINAE; DISEASE MODELS, ANIMAL; DYSENTERY, AMEBIC; ENTAMOEBA HISTOLYTICA; GERM-FREE LIFE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; MICE; MICE, INBRED C3H; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS;

ENTAMOEBA HISTOLYTICA; MURINAE; MUS;

EID: 77956252962     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2010.03.007     Document Type: Article

References (30)

1. Beving D.E., Soong C.J., Ravdin J.I. Oral immunization with a recombinant cysteine-rich section of the Entamoeba histolytica galactose-inhibitable lectin elicits an intestinal secretory immunoglobulin A response that has in vitro adherence inhibition activity. Infection and Immunity 1996, 64:1473-1476.
2. Bruchhaus I., Richter S., Tannich E. Removal of hydrogen peroxide by the 29kDa protein of Entamoeba histolytica. Biochemical Journal 1997, 326:785-789.
3. Carrero J.C., Cervantes-Rebolledo C., Aguilar-Díaz H., Díaz-Gallardo M.Y., Laclette J.P., Morales-Montor J. The role of the secretory immune response in the infection by Entamoeba histolytica. Parasite Immunology 2007, 29:331-338.
4. Carrero J.C., Díaz M.Y., Viveros M., Espinoza B., Acosta E., Ortiz-Ortiz L. Human secretory immunoglobulin A anti-Entamoeba histolytica antibodies inhibit adherence of amebae to MDCK cells. Infection and Immunity 1994, 62:764-767.
5. Carrero J.C., Petrossian P., Acosta E., Sánchez-Zerpa M., Ortiz-Ortiz L., Laclette J.P. Cloning and characterization of Entamoeba histolytica antigens recognized by human secretory IgA antibodies. Parasitology Research 2000, 86:330-334.
6. Chaudhry O.A., Petri W.A. Vaccine prospects for amebiasis. Expert Review of Vaccines 2005, 4:657-668.
7. Dertzbaugh M.T., Elson C.O. Comparative effectiveness of the cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines. Infection and Immunity 1993, 61:48-55.
8. Dertzbaugh M.T., Macrina F.L. Plasmid vectors for constructing translational fusions to the B subunit of cholera toxin. Gene 1989, 82:335-342.
9. Diamond L.S., Harlow D.R., Cunnick C.C. A new medium for the axenic cultivation of Entamoeba histolytica and other Entamoeba. Transactions of the Royal Society of Tropical Medicine and Hygiene 1978, 72:431-432.
10. + T cells. Immunology 2006, 118:311-320.
11. Ghosh P.K., Mancilla R., Ortiz-Ortiz L. Intestinal amebiasis: histopathologic features in experimentally infected mice. Archives of Medical Research 1994, 25:297-302.
12. Guo X., Barroso L., Becker S.M., Lyerly D.M., Vedvick T.S., Reed S.G., Petri W.A., Houpt E.R. Protection against intestinal amebiasis by a recombinant vaccine is transfectable by T cells and mediated by gamma interferon. Infection and Immunity 2009, 77:3909-3918.
13. Halliwell B., Zhao K., Whiteman M. The gastrointestinal tract: a major site of antioxidant action?. Free Radical Research 2000, 33:819-830.
14. Haque R., Ali I.M., Sack R.B., Farr B.M., Ramakrishnan G., Petri W.A. Amebiasis and mucosal IgA antibody against the Entamoeba histolytica adherence lectin in Bangladeshi children. The Journal of Infectious Diseases 2001, 183:1787-1793.
15. Haque R., Duggal P., Ali I.M., Hossain M.B., Mondal D., Sack R.B., Farr B.M., Beaty T.H., Petri W.A. Innate and acquired resistance to amebiasis in Bangladeshi children. The Journal of Infectious Diseases 2002, 186:547-552.
16. Haque R., Ikm A., Petri W.A. Salivary antilectin IgA antibodies in a cohort of children residing in an endemic area of Bangladesh. Archives of Medical Research 2000, 31:S41-S43.
17. Haque R., Mondal D., Duggal P., Kabir M., Roy S., Farr B.M., Sack R.B., Petri W.A. Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infection and Immunity 2006, 74:904-909.
18. Haque R., Mondal D., Kirkpatrick B.D., Akther S., Farr B.M., Sack R.B., Petri W.A. Epidemiologic and clinical characteristics of acute diarrhea with emphasis on Entamoeba histolytica infections in preschool children in an urban slum of Dhaka, Bangladesh. American Journal of Tropical Medicine and Hygiene 2003, 69:398-405.
19. Houpt E., Barroso L., Lockhart L., Wright R., Cramer C., Lyerly D., Petri W.A. Prevention of intestinal amebiasis by vaccination with the Entamoeba histolytica Gal/GalNac lectin. Vaccine 2004, 22:611-617.
20. Lee J., Park S.J., Yong T.S. Serodiagnosis of amoebiasis using a recombinant protein fragment of the 29kDa surface antigen of Entamoeba histolytica. International Journal of Parasitology 2000, 30:1487-1491.
21. Mavris M., Sansonetti P. Microbial-gut interactions in health and disease. Epithelial cell responses. Best Practice & Research Clinical Gastroenterology 2004, 18:373-386.
22. Petri W.A., Chaudhry O., Haque R., Houpt E. Adherence-blocking vaccine for amebiasis. Archives of Medical Research 2006, 37:288-291.
23. Ramos F., Morán P., González E., García G., Ramiro M., Gómez A., de León M.del.C., Melendro E.I., Valadez A., Ximénez C. Entamoeba histolytica and Entamoeba dispar: prevalence infection in a rural Mexican community. Experimental Parasitology 2005, 110:327-330.
24. Ravdin J.I., Abd-Alla M.D., Welles S.L., Reddy S., Jackson T.F. Intestinal antilectin immunoglobulin A antibody response and immunity to Entamoeba dispar infection following cure of amebic liver abscess. Infection and Immunity 2003, 71:6899-6905.
25. Sen A., Chatterjee N.S., Akbar M.A., Nandi N., Das P. The 29-kilodalton thiol-dependent peroxidase of Entamoeba histolytica is a factor involved in pathogenesis and survival of the parasite during oxidative stress. Eukaryotic Cell 2007, 6:664-673.
26. Soong C.J., Torian B.E., Abd-Alla M.D., Jackson T.F., Gatharim V., Ravdin J.I. Protection of gerbils from amebic liver abscess by immunization with recombinant Entamoeba histolytica 29-kilodalton antigen. Infection and Immunity 1995, 63:472-477.
27. Torian B.E., Flores B.M., Stroeher V.L., Hagen F.S., Stamm W.E. CDNA sequence analysis of a 29-kDa cysteine-rich surface antigen of pathogenic Entamoeba histolytica. Proceedings of the National Academy of Science of the United States of America 1990, 87:6358-6362.
28. Walsh J.A. Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. Reviews of Infectious Diseases 1986, 8:228-238.
29. Ximenez C., Moran P., Ramos P., Leyva O., Melendro E.I. Specific anti-E. Histolytica IgA monoclonal antibodies. Advances in Experimental Medicine and Biology 1995, 371B:963-966.
30. Zhang T., Li E., Stanley S.L. Oral immunization with the dodecapeptide repeat of the serine-rich Entamoeba histolytica protein (SREHP) fused to the cholera toxin B subunit induces a mucosal and systemic anti-SREHP antibody response. Infection and Immunity 1995, 63:1349-1355.